Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Raymund R RazonableSidna M Tulledge-ScheitelSara N HansonRichard F ArndtLeigh L SpeicherTeresa A SevilleJennifer J LarsenRavindra GaneshJohn C O'HoroPublished in: Open forum infectious diseases (2022)
This real-world analysis of a large cohort of high-risk patients demonstrates low rates of severe disease after treatment with sotrovimab during the era dominated by Omicron B.1.1.529 and after treatment with bebtelovimab during the era dominated by BA.2 and Omicron subvariants.